These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs. Zeytun A; Nagarkatti M; Nagarkatti PS Blood; 2000 Mar; 95(6):2111-7. PubMed ID: 10706882 [TBL] [Abstract][Full Text] [Related]
7. Fulminant hepatitis by Fas-ligand expression in MRL-lpr/lpr mice grafted with Fas-positive livers and wild-type mice with Fas-mutant livers. Li XK; Fujino M; Sugioka A; Morita M; Okuyama T; Guo L; Funeshima N; Kimura H; Enosawa S; Amemiya H; Suzuki S Transplantation; 2001 Feb; 71(4):503-8. PubMed ID: 11258428 [TBL] [Abstract][Full Text] [Related]
8. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells. Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659 [TBL] [Abstract][Full Text] [Related]
10. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. Hohlbaum AM; Gregory MS; Ju ST; Marshak-Rothstein A J Immunol; 2001 Dec; 167(11):6217-24. PubMed ID: 11714783 [TBL] [Abstract][Full Text] [Related]
12. Fas ligand on tumor cells mediates inactivation of neutrophils. Chen YL; Chen SH; Wang JY; Yang BC J Immunol; 2003 Aug; 171(3):1183-91. PubMed ID: 12874204 [TBL] [Abstract][Full Text] [Related]
13. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Lau HT; Yu M; Fontana A; Stoeckert CJ Science; 1996 Jul; 273(5271):109-12. PubMed ID: 8658177 [TBL] [Abstract][Full Text] [Related]
14. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion. Nyhus JK; Wolford C; Feng L; Barbera-Guillem E Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792 [TBL] [Abstract][Full Text] [Related]
15. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity. Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452 [TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. Delgado M; Ganea D J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved. Kim S; Kim KA; Hwang DY; Lee TH; Kayagaki N; Yagita H; Lee MS J Immunol; 2000 Mar; 164(6):2931-6. PubMed ID: 10706679 [TBL] [Abstract][Full Text] [Related]
18. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts. Djamali A; Odorico JS Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278 [TBL] [Abstract][Full Text] [Related]
19. p53 promotes selection for Fas-mediated apoptotic resistance. Maecker HL; Koumenis C; Giaccia AJ Cancer Res; 2000 Aug; 60(16):4638-44. PubMed ID: 10969818 [TBL] [Abstract][Full Text] [Related]
20. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. Min WP; Gorczynski R; Huang XY; Kushida M; Kim P; Obataki M; Lei J; Suri RM; Cattral MS J Immunol; 2000 Jan; 164(1):161-7. PubMed ID: 10605007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]